{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:34Z","timestamp":1761513214342,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.3816\/cbc.2005.s.006","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T21:20:47Z","timestamp":1221254447000},"page":"S63-S70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S2","title":["Strategies to Prevent Chemotherapy-Induced Bone Loss in Women with Breast Cancer"],"prefix":"10.3816","volume":"5","author":[{"given":"Richard L.","family":"Theriault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2005.s.006_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.1995.13.5.1144","article-title":"Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up","volume":"13","author":"Quiet","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.1989.7.9.1239","article-title":"Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years","volume":"7","author":"Rosen","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib3","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.1991.9.9.1650","article-title":"Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study","volume":"9","author":"Rosen","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomized trials","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","article-title":"Polychemotherapy for early breast cancer: an overview of the randomized trials","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib6","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2003.04.576","article-title":"Meeting highlights: updated international expert panel consensus on the primary therapy of early breast cancer","volume":"21","author":"Goldhirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/mend.13.6.0299","article-title":"The actions and interactions of sex steroids and growth factors\/cytokines on the skeleton","volume":"13","author":"Spelsberg","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.3816\/CBC.2005.s.006_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S8756-3282(98)00077-5","article-title":"Cytokines, bone remodeling, and estrogen deficiency: a 1998 update","volume":"23","author":"Jilka","year":"1998","journal-title":"Bone"},{"key":"10.3816\/CBC.2005.s.006_bib9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/cncr.11745","volume":"98","author":"Baum","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2005.s.006_bib10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.288.15.1889","article-title":"Clinical use of bone densitometry: scientific review","volume":"288","author":"Cummings","year":"2002","journal-title":"JAMA"},{"key":"10.3816\/CBC.2005.s.006_bib13","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/jbmr.5650111215","article-title":"A prospective study on socioeconomic aspects of fracture of the proximal femur","volume":"11","author":"Schurch","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"2A","key":"10.3816\/CBC.2005.s.006_bib14","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"Cooper","year":"1997","journal-title":"Am J Med"},{"key":"10.3816\/CBC.2005.s.006_bib15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2005.s.006_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2005.s.006_bib17","first-page":"82a","article-title":"Bisphosphonates in the reduction of metastases in breast cancer - results of the extended follow-up of the first study population","volume":"19","author":"Diel","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib18","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in nodepositive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0015-0282(16)49268-X","article-title":"Prospects for fertility after chemotherapy or radiation for neoplastic disease","volume":"45","author":"Damewood","year":"1986","journal-title":"Fertil Steril"},{"key":"10.3816\/CBC.2005.s.006_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0039-128X(89)90084-6","article-title":"Chemotherapy-induced premature ovarian failure: mechanisms and prevention","volume":"54","author":"Ataya","year":"1989","journal-title":"Steroids"},{"key":"10.3816\/CBC.2005.s.006_bib22","first-page":"155","article-title":"The effects of cyclophosphamide, azathioprine, and 6-mercaptopurine on oocyte and follicle number in C57BL\/6N mice","volume":"31","author":"Mattison","year":"1981","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.3816\/CBC.2005.s.006_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0890-6238(92)90004-D","article-title":"Reproductive toxicity of cyclophosphamide in the C57BL\/6N mouse: 1. Effects on ovarian structure and function","volume":"6","author":"Plowchalk","year":"1992","journal-title":"Reprod Toxicol"},{"key":"10.3816\/CBC.2005.s.006_bib24","first-page":"125","article-title":"Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects","volume":"16","author":"Reichman","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.3816\/CBC.2005.s.006_bib25","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.1999.17.8.2365","article-title":"Risk of menopause during the first year after breast cancer diagnosis","volume":"17","author":"Goodwin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib29","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2005.s.006_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2005.s.006_bib34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib35","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(00)02263-7","article-title":"Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials","volume":"355","author":"Early Breast Cancer Trialist's Collaborative Group","year":"2000","journal-title":"Lancet"},{"key":"10.3816\/CBC.2005.s.006_bib36","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal-related complications in patients with breast cancer and lytic bone lesions","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2005.s.006_bib37","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2005.s.006_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.3816\/CBC.2005.s.006_bib40","first-page":"S233","article-title":"Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): preliminary results of the Z-FAST trial","volume":"88","author":"Brufsky","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"10.3816\/CBC.2005.s.006_bib41","first-page":"S8","volume":"88","author":"Gnant","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2005.s.006_bib42","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib43","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"suppl 10","key":"10.3816\/CBC.2005.s.006_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminoncol.2004.07.030","article-title":"Profiling the safety and tolerability of bisphosphonates","volume":"31","author":"Body","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.3816\/CBC.2005.s.006_bib46","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphanates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.s.006_bib47","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.3816\/CBC.2005.s.006_bib48","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911706954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:08Z","timestamp":1761513008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911706954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":48,"alternative-id":["S1526820911706954"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2005.s.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to Prevent Chemotherapy-Induced Bone Loss in Women with Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2005.s.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}